Vuélvete ilimitado con Magzter GOLD

Vuélvete ilimitado con Magzter GOLD

Obtenga acceso ilimitado a más de 9000 revistas, periódicos e historias Premium por solo

$149.99
 
$74.99/Año

Intentar ORO - Gratis

Time to build Indian Medtech industry to global reckoning

Bio Spectrum

|

May 2020

India has built amazing infrastructure of science especially interdisciplinary and translational aspects of biology in the last 15 years despite history of low level of investments both in R&D (0.8 per cent of the GDP) as well as healthcare (1.3 per cent of the GDP). This needs to change not just as a stopgap measure but greater investment, consistently over a longerrange horizon, is important. And there is need to leverage the strengths and find strategic responses to the gaps in a mission mode.

Time to build Indian Medtech industry to global reckoning

Over the last decade there has been a major push to develop homegrown medtech product startups in healthcare and other areas of biotech. Several agencies notably Department of Science & Technology (DST), Department of Biotechnology- Biotechnology Industry Research Assistance Council (DBT-BIRAC), Millennium Alliance, Indo-U.S. Science and Technology Forum (IUSSTF), Atal Innovation Mission (AIM)-Niti Aayog and others have contributed to injecting funding and other support mechanisms to build 3000- 4000 biotech/medtechstartups as well as 200 S&T incubators in the country.

This arguably is a national portfolio that has been built through taxpayer's money and painstaking efforts of various stakeholders, most notably the leadership shown by incubators. The incubators housing them are analogous to an “asset house”.

The innovation community has responded with a can-do attitude and have scrambled to kick start COVID-19 focused solutions. The Principal Scientific Adviser’s (PSA) Office has constituted several task forces that are co-ordinating different aspects of the response with speed and precision.

COVID-19 Funding: Fast decisions

Most Science & Technology arms of the Government of India have launched COVID-19 specific funding calls, be it CAWACH by DST, Council of Scientific and Industrial Research (CSIR) labs, DBT-BIRAC (a special COVID-19 call), Technology Development Board (TDB) and Invest India as well as big incubators such as IKP Knowledge Park (IKP), Venture Center, SINE-IIT Bombay, Centre for Cellular and Molecular Platforms (C-CAMP), SIIC- IIT Kanpur, AIC-CCMB and FITT-IIT Delhi amongst others.

MÁS HISTORIAS DE Bio Spectrum

Bio Spectrum

Bio Spectrum

Building Breakthrough Medical Devices

Dr Ria Khurana founded RNT Health Insights, a Chandigarh-based healthtech startup specialising in Al-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures, in 2022 along with Dr Tanmaya Gulati.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

Bridging classical epidemiology with modern science

A physician scientist with a MBBS from Lady Hardinge Medical College, (University of Delhi), a post-graduation in Paediatrics and a PhD from All India Institute of Medical Sciences (AIIMS), New Delhi, Prof.Shinjini Bhatnagar served as Professor of Eminence at Translational Health Science and Technology Institute (THSTI) until February 2023 and was subsequently appointed Distinguished Professor at THSTI until May 2025.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

"AI, Automation & Analytics: A new era of modern microbiology testing!"

Pharmaceutical manufacturing is undergoing a paradigm shift.

time to read

4 mins

January 2026

Bio Spectrum

Bio Spectrum

The CRISPR Moment

CRISPR (clustered regularly interspaced short palindromic repeats) technology is ushering in a new era of gene and cell therapy, offering more precision and potential for treating genetic disorders, cancer, and infectious diseases.

time to read

2 mins

January 2026

Bio Spectrum

Leveraging Microfluidic Technology for mRNA-LNP Manufacturing

Over the past five years, messenger RNA (mRNA) therapeutics have evolved from experimental concepts into lifesaving medicines.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

Demonstrating India's Vaccine Capabilities

Havisure is India's first and only indigenously developed Hepatitis A vaccine, to address one of the country's most persistent public health challengeswidespread Hepatitis A infections caused by inadequate sanitation and contaminated food and water.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

Inspiring Future Generations

A PhD in molecular biology from the University of Cambridge, UK, Prof. Gaiti Hasan is a Distinguished Fellow at the National Centre for Biological Sciences (NCBS), Bengaluru.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

A Landmark for India's Antibiotic Innovation

After three decades of research and hard work, India has led the way with the creation of Nafithromycin, the country's first indigenous antibiotic.

time to read

2 mins

January 2026

Bio Spectrum

Bio Spectrum

"Future vaccine innovation will be integration of R&D, regulatory support and manufacturing”

TechInvention Lifecare Limited, a vaccine focused biotechnology company headquartered in Mumbai, is recognised for its innovative contributions to global healthcare.

time to read

4 mins

January 2026

Bio Spectrum

Bio Spectrum

Telangana: Building India's Most Credible Life Sciences Ecosystem

Telangana's recognition as BioSpectrum India's Best Performing State in Life Sciences 2025 is a timely validation of the direction the state has taken in recent years-one anchored in execution, responsiveness, and a clear understanding of where global life sciences value chains are headed.

time to read

4 mins

January 2026

Translate

Share

-
+

Change font size